Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 8, 2008 - Issue 1
Submit an article Journal homepage
428
Views
71
CrossRef citations to date
0
Altmetric
Reviews

Galectin-1 as a potential therapeutic target in autoimmune disorders and cancer

Mariana Salatino Instituto de Biología y Medicina Experimental (IBYME), Laboratorio de Inmunopatología, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
,
Diego O Croci Instituto de Biología y Medicina Experimental (IBYME), Laboratorio de Inmunopatología, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
,
Germán A Bianco Instituto de Biología y Medicina Experimental (IBYME), Laboratorio de Inmunopatología, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
,
Juan M Ilarregui Instituto de Biología y Medicina Experimental (IBYME), Laboratorio de Inmunopatología, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
,
Marta A Toscano Instituto de Biología y Medicina Experimental (IBYME), Laboratorio de Inmunopatología, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina
&
Gabriel A Rabinovich Instituto de Biología y Medicina Experimental (IBYME), Laboratorio de Inmunopatología, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Argentina; Universidad de Buenos Aires, Departmento de Química Biológica, Facultad de Ciencias Exactas y Naturales, C1428ADN, Ciudad de Buenos Aires, Argentina; Professor of Immunology Instituto de Biología y Medicina Experimental (IBYME), CONICET. Vuelta de Obligado 2490 (C1428ADN), Buenos Aires, Argentina +54 11 4783 2869 (Int. 236); +54 11 4786 2564; [email protected]
, PhD
Pages 45-57 | Published online: 17 Dec 2007

Bibliography

  • Cooper DN. Galectinomics: finding themes in complexity. Biochim Biophys Acta 2002;1572(2-3):209-31
  • Leffler H, Carlsson S, Hedlund M, Qian Y, Poirier F. Introduction to galectins. Glycoconj J 2004;19(7-9):433-40
  • Ilarregui JM, Bianco GA, Toscano MA, Rabinovich GA. The coming of age of galectins as immunomodulatory agents: impact of these carbohydrate binding proteins in T cell physiology and chronic inflammatory disorders. Ann Rheum Dis 2005;64(Suppl 4):iv96-iv103
  • Toscano MA, Ilarregui JM, Bianco GA, et al. Dissecting the pathophysiologic role of endogenous lectins: glycan-binding proteins with cytokine-like activity? Cytokine Growth Factor Rev 2007;18(1-2):57-71
  • Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002;1572(2-3):263-73
  • Brewer CF, Miceli MC, Baum LG. Clusters, bundles, arrays and lattices: novel mechanisms for lectin-saccharide-mediated cellular interactions. Curr Opin Struct Biol 2002;12(5):616-23
  • Liu FT, Rabinovich GA. Galectins as modulators of tumour progression. Nat Rev Cancer 2005;5(1):29-41
  • Rabinovich GA, Iglesias MM, Modesti NM, et al. Activated rat macrophages produce a galectin-1-like protein that induces apoptosis of T cells: biochemical and functional characterization. J Immunol 1998;160(10):4831-40
  • Zuniga E, Rabinovich GA, Iglesias MM, Gruppi A. Regulated expression of galectin-1 during B-cell activation and implications for T-cell apoptosis. J Leuk Biol 2001;70(1):73-9
  • Blaser C, Kaufmann M, Muller C, et al. Beta-galactoside-binding protein secreted by activated T cells inhibits antigen-induced proliferation of T cells. Eur J Immunol 1998;28(8):2311-19
  • Garin MI, Chu CC, Golshayan D, et al. Galectin-1: a key effector of regulation mediated by CD4+CD25+ T cells. Blood 2007;109(5):2058-65
  • Sugimoto N, Oida T, Hirota K, et al. Foxp3-dependent and -independent molecules specific for CD25+CD4+ natural regulatory T cells revealed by DNA microarray analysis. Int Immunol 2006;18(8):1197-209
  • Wang JL, Gray RM, Haudek KC, Patterson RJ. Nucleocytoplasmic lectins. Biochim Biophys Acta 2004;1673(1-2):75-93
  • Dagher SF, Wang JL, Patterson RJ. Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci USA 1995;92(4):1213-17
  • Hughes RC. Secretion of the galectin family of mammalian carbohydrate-binding proteins. Biochim Biophys Acta 1999;1473(1):172-85
  • Seelenmeyer C, Wegehingel S, Tews I, et al. Cell surface counter receptors are essential components of the unconventional export machinery of galectin-1. J Cell Biol 2005;171(2):373-81
  • Elola MT, Wolfenstein-Todel C, Troncoso MF, Vasta GR, Rabinovich GA. Galectins: matricellular glycan-binding proteins linking cell adhesion, migration, and survival. Cell Mol Life Sci 2007;64(13):1679-700
  • Nickel W. Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells. Traffic 2005;6(8):607-14
  • Rabinovich GA, Baum LG, Tinari N, et al. Galectins and their ligands: amplifiers, silencers or tuners of the inflammatory response? Trends Immunol 2002;23(6):313-20
  • Camby I, Mercier ML, Lefranc F, Kiss R. Galectin-1: A small protein with major functions. Glycobiology 2006;16(11):137-57
  • Levi G, Tarrab-Hazdai R, Teichberg VI. Prevention and therapy with electrolectin of experimental autoimmune myasthenia gravis in rabbits. Eur J Immunol 1983;13(6):500-7
  • Offner H, Celnik B, Bringman TS, et al. Recombinant human β-galactoside binding lectin suppresses clinical and histological signs of experimental autoimmune encephalomyelitis. J Neuroimmunol 1990;28(2):177-84
  • Rabinovich GA, Daly G, Dreja H, et al. Recombinant galectin-1 and its genetic delivery suppress collagen-induced arthritis via T cell apoptosis. J Exp Med 1999;190(3):385-98
  • Santucci L, Fiorucci S, Rubinstein N, et al. Galectin-1 suppresses experimental colitis in mice. Gastroenterology 2003;124(5):1381-94
  • Toscano MA, Commodaro AG, Ilarregui JM, et al. Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J Immunol 2006;176(10):6323-32
  • Santucci L, Fiorucci S, Cammilleri F, et al. Galectin-1 exerts immunomodulatory and protective effects on concanavalin A-induced hepatitis in mice. Hepatology 2000;31(2):399-406
  • Perone MJ, Larregina AT, Shufesky WJ, et al. Transgenic galectin-1 induces maturation of dendritic cells that elicit contrasting responses in naive and activated T cells. J Immunol 2006;176(12):7207-20
  • Rubinstein N, Alvarez M, Zwirner NW, et al. Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 2004;5(3):241-51
  • Le QT, Shi G, Cao H, et al. Galectin-1: a link between tumor hypoxia and tumor immune privilege. J Clin Oncol 2005;23(35):8932-41
  • Perillo NL, Pace KE, Seilhamer JJ, Baum LG. Apoptosis of T cells mediated by galectin-1. Nature 1995;378(6558):736-9
  • Rabinovich GA, Ariel A, Hershkoviz R, et al. Specific inhibition of T-cell adhesion to extracellular matrix and proinflammatory cytokine secretion by human recombinant galectin-1. Immunology 1999;97(1):100-6
  • He J, Baum LG. Presentation of galectin-1 by extracellular matrix triggers T cell death. J Biol Chem 2004;279(6):4705-12
  • Endharti AT, Zhou YW, Nakashima I, Suzuki H. Galectin-1 supports survival of naive T cells without promoting cell proliferation. Eur J Immunol 2005;35(1):86-97
  • Matarrese P, Tinari A, Mormone E, et al. Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem 2005;280(8):6969-85
  • Toscano MA, Bianco GA, Ilarregui JM et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 2007;8(8):825-34
  • Pace KE, Lee C, Stewart PL, Baum LG. Restricted receptor segregation into membrane microdomains occurs on human T cells during apoptosis induced by galectin-1. J Immunol 1999;163(7):3801-11
  • Galvan M, Tsuboi S, Fukuda M, Baum LG. Expression of a specific glycosyltransferase enzyme regulates T cell death mediated by galectin-1. J Biol Chem 2000;275(22):16730-7
  • Amano M, Galvan M, He J, Baum LG. The ST6Gal I sialyltransferase selectively modifies N-glycans on CD45 to negatively regulate galectin-1-induced CD45 clustering, phosphatase modulation, and T cell death. J Biol Chem 2003;278(9):7469-75
  • Perillo NL, Uittenbogaart CH, Nguyen JT, Baum LG. Galectin-1, an endogenous lectin produced by thymic epithelial cells, induces apoptosis of human thymocytes. J Exp Med 1997;185(10):1851-8
  • Rabinovich GA, Modesti NM, Castagna LF, et al. Specific inhibition of lymphocyte proliferation and induction of apoptosis by CLL-I, a β-galactoside-binding lectin. J Biochem 1997;122(2):365-73
  • Chung CD, Patel VP, Moran M, Lewis LA, Miceli MC. Galectin-1 induces partial TCR zeta-chain phosphorylation and antagonizes processive TCR signal transduction. J Immunol 2000;165(7):3722-9
  • Rabinovich GA, Alonso CR, Sotomayor CE, et al. Molecular mechanisms implicated in galectin-1-induced apoptosis: activation of the AP-1 transcription factor and downregulation of Bcl-2. Cell Death Differ 2000;7(8):747-53
  • Ion G, Fajka-Boja R, Toth GK, Caron M, Monostori E. Role of p56lck and ZAP70-mediated tyrosine phosphorylation in galectin-1-induced cell death. Cell Death Differ 2005;12(8):1145-7
  • Ion G, Fajka-Boja R, Kovacs F, et al. Acid sphingomyelinase mediated release of ceramide is essential to trigger the mitochondrial pathway of apoptosis by galectin-1. Cell Signal 2006;18(11):1887-96
  • Stowell SR, Karmakar S, Stowell CJ, et al. Human galectin-1, -2, and -4 induce surface exposure of phosphatidylserine in activated human neutrophils but not in activated T cells. Blood 2007;109(1):219-27
  • He J, Baum LG. Endothelial cell expression of galectin-1 induced by prostate cancer cells inhibits T-cell transendothelial migration. Lab Invest 2006;86(6):578-90
  • Sakaguchi S. Naturally arising CD4+ regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-62
  • Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6(4):295-307
  • Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10(9):942-9
  • Colnot C, Ripoche MA, Scaerou F, Foulis D, Poirier F. Galectins in mouse embryogenesis. Biochem Soc Trans 1996;24(1):141-6
  • Tang J, Zhu W, Silver PB, et al. Autoimmune uveitis elicited with antigen-pulsed dendritic cells has a distinct clinical signature and is driven by unique effector mechanisms: initial encounter with autoantigen defines disease phenotype. J Immunol 2007;178(9):5578-87
  • Van Der Leij J, Van Den Berg A, Harms G, et al. Strongly enhanced IL-10 production using stable galectin-1 homodimers. Mol Immunol 2007;44(4):506-13
  • Perone MJ, Bertera S, Tawadrous ZS, et al. Dendritic cells expressing transgenic galectin-1 delay onset of autoimmune diabetes in mice. J Immunol 2006;177(8):5278-89
  • Baum LG, Blackall DP, Arias-Magallano S, et al. Amelioration of graft versus host disease by galectin-1. Clin Immunol 2003;109(3):295-307
  • Jenner J, Kerst G, Handgretinger R, Muller I. Increased α2,6-sialylation of surface proteins on tolerogenic, immature dendritic cells and regulatory T cells. Exp Hematol 2006;34(9):1212-18
  • Danguy A, Camby I, Kiss R. Galectins and cancer. Biochim Biophys Acta 2002;1572(2-3):285-93
  • Lahm H, Andre S, Hoeflich A, et al. Tumor galectinology: insights into the complex network of a family of endogenous lectins. Glycoconj J 2004;20(4):227-38
  • Saussez S, Camby I, Toubeau G, Kiss R. Galectins as modulators of tumor progression in head and neck squamous cell carcinomas. Head Neck 2007;29(9):874-84
  • Paz A, Haklai R, Elad-Sfadia G, Ballan E, Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001;20(51):7486-93
  • Prior IA, Muncke C, Parton RG, Hancock JF. Direct visualization of Ras proteins in spatially distinct cell surface microdomains. J Cell Biol 2003;160(2):165-70
  • Van Den Brule F, Califice S, Castronovo V. Expression of galectins in cancer: a critical review. Glycoconj J 2004;19(7-9):537-42
  • Camby I, Belot N, Rorive S, et al. Galectins are differentially expressed in supratentorial pilocytic astrocytomas, astrocytomas, anaplastic astrocytomas and glioblastomas, and significantly modulate tumor astrocyte migration. Brain Pathol 2001;11(1):12-26
  • Lahm H, Andre S, Hoeflich A, et al. Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures. J Cancer Res Clin Oncol 2001;127(6):375-86
  • Camby I, Belot N, Lefranc F, et al. Galectin-1 modulates human glioblastoma cell migration into the brain through modifications to the actin cytoskeleton and levels of expression of small GTPases. J Neuropathol Exp Neurol 2002;61(7):585-96
  • Van Den Brule FA, Waltregny D, Castronovo V. Increased expression of galectin-1 in carcinoma-associated stroma predicts poor outcome in prostate carcinoma patients. J Pathol 2001;193(1):80-7
  • Jung EJ, Moon HG, Cho BI, et al. Galectin-1 expression in cancer-associated stromal cells correlates tumor invasiveness and tumor progression in breast cancer. Int J Cancer 2007;120(11):2331-8
  • Rabinovich GA. Galectin-1 as a potential cancer target. Br J Cancer 2005;92(7):1188-92
  • Chen YR, Juan HF, Huang HC, et al. Quantitative proteomic and genomic profiling reveals metastasis-related protein expression patterns in gastric cancer cells. J Proteome Res 2006;5(10):2727-42
  • Kreunin P, Yoo C, Urquidi V, Lubman DM, Goodison S. Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics 2007;7(2):299-312
  • Puchades M, Nilsson CL, Emmett MR, et al. Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. J Proteome Res 2007;6(2):869-75
  • Camby I, Decaestecker C, Lefranc F, et al. Galectin-1 knocking down in human U87 glioblastoma cells alters their gene expression pattern. Biochem Biophys Res Commun 2005;335(1):27-35
  • Saussez S, Lorfevre F, Lequeux T, et al. The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol 2007:[Epub ahead of print]
  • Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol 2007;25:267-96
  • Croci DO, Zacarias Fluck MF, Rico MJ, et al. Dynamic cross-talk between tumor and immune cells in orchestrating the immunosuppressive network at the tumor microenvironment. Cancer Immunol Immunother 2007;56(11):1687-700
  • Daroqui CM, Ilarregui JM, Rubinstein N, et al. Regulation of galectin-1 expression by transforming growth factor β1 in metastatic mammary adenocarcinoma cells: implications for tumor-immune escape. Cancer Immunol Immunother 2007;56(4):491-99
  • Zacarias Fluck MF, Rico MJ, Gervasoni SI, et al. Low-dose cyclophosphamide modulates galectin-1 expression and function in an experimental rat lymphoma model. Cancer Immunol Immunother 2007;56(2):237-48
  • Lu Y, Lotan D, Lotan R. Differential regulation of constitutive and retinoic acid-induced galectin-1 gene transcription in murine embryonal carcinoma and myoblastic cells. Biochim Biophys Acta 2000;1491(1-3):13-19
  • Juszczynski P, Ouyang J, Monti S, et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci USA 2007;104(32):134-9
  • Gandhi MK, Moll G, Smith C, et al. Galectin-1 mediated suppression of Epstein–Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007;110(4):1326-9
  • Thijssen VL, Postel R, Brandwijk RJ, et al. Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 2006;103(43):15975-80
  • Valenzuela HF, Pace KE, Cabrera PV, et al. O-glycosylation regulates LNCaP prostate cancer cell susceptibility to apoptosis induced by galectin-1. Cancer Res 2007;67(13):6155-62
  • Barrionuevo P, Beigier-Bompadre M, Ilarregui JM, et al. A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J Immunol 2007;178(1):436-45
  • Correa SG, Sotomayor CE, Aoki MP, Maldonado CA, Rabinovich GA. Opposite effects of galectin-1 on alternative metabolic pathways of L-arginine in resident, inflammatory, and activated macrophages. Glycobiology 2003;13(2):119-28
  • Hittelet A, Legendre H, Nagy N, et al. Upregulation of galectins-1 and -3 in human colon cancer and their role in regulating cell migration. Int J Cancer 2003;103(3):370-9
  • Sanford GL, Harris-Hooker S. Stimulation of vascular cell proliferation by β-galactoside specific lectins. FASEB J 1990;4(11):2912-18
  • Moiseeva EP, Javed Q, Spring EL, De Bono DP. Galectin 1 is involved in vascular smooth muscle cell proliferation. Cardiovasc Res 2000;45(2):493-502
  • Maeda N, Kawada N, Seki S, et al. Stimulation of proliferation of rat hepatic stellate cells by galectin-1 and galectin-3 through different intracellular signaling pathways. J Biol Chem 2003;278(21):18938-44
  • Kopitz J, Von Reitzenstein C, Andre S, et al. Negative regulation of neuroblastoma cell growth by carbohydrate-dependent surface binding of galectin-1 and functional divergence from galectin-3. J Biol Chem 2001;276(38):35917-23
  • Yamaoka K, Mishima K, Nagashima Y, et al. Expression of galectin-1 mRNA correlates with the malignant potential of human gliomas and expression of antisense galectin-1 inhibits the growth of 9 glioma cells. J Neurosci Res 2000;59(6):722-30
  • Strik HM, Schmidt K, Lingor P, et al. Galectin-1 expression in human glioma cells: modulation by ionizing radiation and effects on tumor cell proliferation and migration. Oncol Rep 2007;18(2):483-8
  • Wells V, Davies D, Mallucci L. Cell cycle arrest and induction of apoptosis by β-galactoside binding protein (β-GBP) in human mammary cancer cells. A potential new approach to cancer control. Eur J Cancer 1999;35(6):978-83
  • Adams L, Scott GK, Weinberg CS. Biphasic modulation of cell growth by recombinant human galectin-1. Biochim Biophys Acta 1996;1312(2):137-44
  • Van Den Brule FA, Buicu C, Baldet M, et al. Galectin-1 modulates human melanoma cell adhesion to laminin. Biochem Biophys Res Commun 1995;209(2):760-7
  • Zhou Q, Cummings RD. L-14 lectin recognition of laminin and its promotion of in vitro cell adhesion. Arch Biochem Biophys 1993;300(1):6-17
  • Tinari N, Kuwabara I, Huflejt ME, et al. Glycoprotein 90K/MAC-2BP interacts with galectin-1 and mediates galectin-1-induced cell aggregation. Int J Cancer 2001;91(2):167-72
  • Glinsky VV, Huflejt ME, Glinsky GV, Deutscher SL, Quinn TP. Effects of Thomsen-Friedenreich antigen-specific peptide P-30 on β-galactoside-mediated homotypic aggregation and adhesion to the endothelium of MDA-MB-435 human breast carcinoma cells. Cancer Res 2000;60(10):2584-8
  • Clausse N, Van Den Brule F, Waltregny D, Garnier F, Castronovo V. Galectin-1 expression in prostate tumor-associated capillary endothelial cells is increased by prostate carcinoma cells and modulates heterotypic cell-cell adhesion. Angiogenesis 1999;3(4):317-25
  • La M, Cao TV, Cerchiaro G, et al. A novel biological activity for galectin-1: inhibition of leukocyte-endothelial cell interactions in experimental inflammation. Am J Pathol 2003;163(4):1505-15
  • Rabinovich GA, Sotomayor CE, Riera CM, Bianco I, Correa SG. Evidence of a role for galectin-1 in acute inflammation. Eur J Immunol 2000;30(5):1331-9
  • Delbrouck C, Doyen I, Belot N, et al. Galectin-1 is overexpressed in nasal polyps under budesonide and inhibits eosinophil migration. Lab Invest 2002;82(2):147-58
  • Ingrassia L, Camby I, Lefranc F, et al. Anti-galectin compounds as potential anti-cancer drugs. Curr Med Chem 2006;13(29):3513-27
  • Sorne P, Kahl-Knutsson B, Wellmar U, et al. Design and synthesis of galectin inhibitors. Methods Enzymol 2003;363:157-69
  • Rabinovich GA, Cumashi A, Bianco GA et al. Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis. Glycobiology 2006;16(3):210-20

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.